Taro Pharmaceutical Industries Ltd (TARO) Return on Equity ROE from the fourth quarter 2023 to fourth quarter 2022 and annually, average high and low, overall ranking from Mar 31 2023 to Mar 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Taro Pharmaceutical Industries Ltd  (NYSE: TARO)

Taro Pharmaceutical Industries Ltd's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Taro Pharmaceutical Industries Ltd in the fourth quarter 2023?
Taro Pharmaceutical Industries Ltd achieved a return on average equity (ROE) of 1.47 % in its fourth quarter 2023, which is below Taro Pharmaceutical Industries Ltd's average return on equity, which stands at 16.31%.

ROE fell compared to the third quarter 2023, despite the net income growth of % from the third quarter 2023.

Within the Major Pharmaceutical Preparations industry 64 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2023 from 0 to 2248.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2023)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Mar 31 2022)
IV. Quarter
Y / Y Equity Change 1.13 % 2.09 % 2.09 % 2.09 % -
Y / Y Net Income Change -56.33 % - - - -
Net Income (TTM) in Millions 25 58 58 58 58
Return On Equity (TTM) 1.47 % 3.38 % 3.39 % 3.41 % 3.43 %
TARO's Total Ranking # 2248 # 0 # 0 # 0 # 2275
Equity (TTM) in Millions 1,731 1,731 1,731 1,731 1,711
Seq. Equity Change 0 % 0 % 0 % 1.13 % 0.94 %
Seq. Net Income Change - - - - -

Back to TARO Management Effectiveness >> TARO's 5 Years Annual ROE >> Compare TARO ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 65
Sector # 174
Overall # 2248

Return On Equity Statistics
High Average Low
42.84 %
16.31 %
-23.64 %
(Mar 31 2013)   (Mar 31 2021)





TARO Annual Return On Equity (Mar 31 2023)
2023		 (Mar 31 2022)
2022		 (Mar 31 2021)
2021		 (Mar 31 2020)
2020		 (Mar 31 2019)
2019
Total Equity in Millions 1,731 1,711 1,695 2,110 1,911
Y / Y Equity Change 1.13 % 0.94 % -19.64 % 10.39 % -13.54 %
Net Income in Millions 25 58 -401 245 282
Y / Y Net Income Change -56.33 % - - -13.32 % 34.29 %
Return On Equity 1.47 % 3.4 % -23.64 % 11.59 % 14.76 %

Back to TARO Management Effectiveness >> TARO's 5 Years Annual ROE >> Compare TARO ROE to its Competitors




Annual Roe Comment
In 2023 ROE decreased compared to the previous year to 1.47 %, due to deterioration of net income.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
TARO's' Return on Equity at Yahoo Finance
TARO's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for TARO's Competitors
Subscribers only: Roe for Taro Pharmaceutical Industries Ltd's Suppliers
Subscribers only: Return On Equity for TARO's Customers




Companies with similar Return On Equity at Mar 31 2023, within Healthcare Sector ROE
Neurocrine Biosciences Inc   4.02 %
The Cooper Companies Inc   4.00 %
Pacific Health Care Organization Inc  3.85 %
Kewaunee Scientific Corporation  3.82 %
Zimmer Biomet Holdings Inc   3.71 %
Avanos Medical Inc   3.55 %
National Vision Holdings Inc   3.36 %
Ligand Pharmaceuticals Incorporated  3.35 %
Nature s Sunshine Products inc   3.10 %
Vanda Pharmaceuticals Inc   3.06 %
Schrodinger Inc   2.89 %
Privia Health Group Inc   2.44 %
Quidelortho Corp  2.39 %
Nuvasive Inc  2.37 %
Radnet Inc   2.31 %
Adapthealth Corp   2.21 %
Surgery Partners Inc   1.81 %
National Healthcare Corp  1.80 %
Iteos Therapeutics Inc   1.78 %
Steris Plc  1.74 %
Lakeland Industries Inc   1.72 %
China Health Industries Holdings Inc   1.69 %
Biomarin Pharmaceutical Inc  1.56 %
Taro Pharmaceutical Industries Ltd  1.47 %
Orthopediatrics Corp  1.04 %
Nevro Corp   0.78 %
Penumbra Inc  0.65 %

Date modified: 2023-06-30T08:25:33+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.